Glyceryl Monostearate based Solid Lipid Nanoparticles for Controlled Delivery of Docetaxel.
GMS
SLNs
breast cancer
controlled drug delivery
docetaxel
hot melt encapsulation
ovarian cancer.
Journal
Current drug delivery
ISSN: 1875-5704
Titre abrégé: Curr Drug Deliv
Pays: United Arab Emirates
ID NLM: 101208455
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
07
2020
revised:
06
10
2020
accepted:
15
11
2020
pubmed:
5
2
2021
medline:
14
1
2022
entrez:
4
2
2021
Statut:
ppublish
Résumé
Solid lipid nanoparticles (SLNs) is the drug delivery system that has the capability to improve drug release at the desired tumor site. The aim of the present study is to develop glyceryl monostearate (GMS) based SLNs for the controlled delivery of docetaxel. Hot melt encapsulation (HME) method was employed avoiding the use of organic solvents and, therefore, regarded as green synthesis of SLNs. Optimized DTX-SLNs showed desirable size (100 nm) with low poly dispersity index and excellent entrapment efficiency. Surface charge confirmed the stability of formulation. transmission electron microscope (TEM) analysis showed spherical shaped particles and fourier transform infrared microscopy (FTIR) revealed compatibility among formulation excipients. Differential scanning calorimeter (DSC) analysis revealed that the melting transition peak of optimized formulation was also greater than 40°C indicating that SLNs would be solid at body temperature. In-vitro release profile (68% in 24 hours) revealed the controlled release profile of DTX-SLNs, indicating lipophilic docetaxel drug was entrapped inside high melting point lipid core. Cytotoxicity study revealed that blank SLNs were found to be biocompatible while dose dependent cytotoxicity was shown by DTX-SLNs. These studies suggest that DTX-SLNs have the potential for controlled delivery of docetaxel and improved therapeutic outcome.
Sections du résumé
BACKGROUND
BACKGROUND
Solid lipid nanoparticles (SLNs) is the drug delivery system that has the capability to improve drug release at the desired tumor site. The aim of the present study is to develop glyceryl monostearate (GMS) based SLNs for the controlled delivery of docetaxel.
METHODS
METHODS
Hot melt encapsulation (HME) method was employed avoiding the use of organic solvents and, therefore, regarded as green synthesis of SLNs.
RESULTS
RESULTS
Optimized DTX-SLNs showed desirable size (100 nm) with low poly dispersity index and excellent entrapment efficiency. Surface charge confirmed the stability of formulation. transmission electron microscope (TEM) analysis showed spherical shaped particles and fourier transform infrared microscopy (FTIR) revealed compatibility among formulation excipients. Differential scanning calorimeter (DSC) analysis revealed that the melting transition peak of optimized formulation was also greater than 40°C indicating that SLNs would be solid at body temperature. In-vitro release profile (68% in 24 hours) revealed the controlled release profile of DTX-SLNs, indicating lipophilic docetaxel drug was entrapped inside high melting point lipid core. Cytotoxicity study revealed that blank SLNs were found to be biocompatible while dose dependent cytotoxicity was shown by DTX-SLNs.
CONCLUSION
CONCLUSIONS
These studies suggest that DTX-SLNs have the potential for controlled delivery of docetaxel and improved therapeutic outcome.
Identifiants
pubmed: 33538673
pii: CDD-EPUB-113926
doi: 10.2174/1567201818666210203180153
doi:
Substances chimiques
Drug Carriers
0
Glycerides
0
Lipid Nanoparticles
0
Lipids
0
Liposomes
0
Docetaxel
15H5577CQD
glyceryl monostearate
230OU9XXE4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1368-1376Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.